BioCentury | Apr 9, 2021
Deals

April 8 Quick Takes: Hologic buying Mobidiag for nearly $800M; plus Biogen-Bio-Thera, Dicerna royalty sale, a SPAC for LumiraDx, Cidara-Janssen and Chi-Med’s $100M

...This article has been updated to reflect that Dicerna is eligible for $60 million in milestones...
...in Phase III testing.Dicerna sells Oxlumo royalty rightsRoyalty Pharma plc (NASDAQ:RPRX) acquired the royalty interest of Dicerna Pharmaceuticals Inc....
...a 2020 non-exclusive IP deal between Dicerna and Alnylam related to the companies’ PH programs. Dicerna...
BioCentury | Oct 15, 2020
Product Development

Lingering questions as Vertex sheds $15B after Phase II setback

...AAT therapies, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and Dicerna Pharmaceuticals Inc....
...$300 million.That deal came six months after Dicerna...
BioCentury | Oct 9, 2020
Deals

Arrowhead gains Takeda firepower as it seeks edge over Dicerna in AAT-associated liver disease

...Takeda that could help it compete with Dicerna...
...exclusive rights. The deal comes six months after Dicerna Pharmaceuticals Inc....
...—its own DCR-A1AT, and Alnylam's ALN-AAT02. Dicerna...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

...manufacturing facility in Ireland, which it says will be operational in 2021. RNAi therapeutics company Dicerna Pharmaceuticals Inc....
...autoimmune diseases (see “Kira: Depleting Activated Dendritic Cells” ). Robin Sawka, BioCentury Staff Alexion Pharmaceuticals Inc. WuXi Biologics Inc. Dicerna Pharmaceuticals Inc. Valneva...
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...was director of the Center for Lymphoid Malignancies at Columbia University Medical Center. RNAi company Dicerna Pharmaceuticals Inc....
...of commercial development at Pfizer Inc. (NYSE:PFE) in 2009-12. Robin Sawka, BioCentury Staff TG Therapeutics Inc. FogPharma Gemini Therapeutics Inc. Dicerna Pharmaceuticals Inc. Lodo...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...and technical operations, effective May 4. Guyer was SVP of operations at BMS. RNAi company Dicerna Pharmaceuticals Inc....
...Nash will temporarily assume the role of executive chairman. Robin Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix...
BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

...in Europe” ). Alnylam, Dicerna developing RNAi liver disease therapies Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Dicerna Pharmaceuticals Inc....
...the pair also granted each other non-exclusive cross-licenses to their respective primary hyperoxaluria (PH) programs. Dicerna...
...opt in to ex-U.S. commercialization of the selected candidate. The cross-licenses for Alnylam's lumasiran and Dicerna's...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...those programs.” Nodelman’s RNA interests include Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Dicerna Pharmaceuticals Inc....
...by Novartis AG (NYSE:NVS) for $9.7 billion. An updated regulatory plan has not been disclosed. Dicerna...
BioCentury | Jan 11, 2020
Company News

Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV

...oligonucleotide stabilization technology in-licensed from Osaka University-spinout Luxna Biotech Co. Ltd. Several other companies, including Dicerna Pharmaceuticals Inc....
BioCentury | Nov 18, 2019
Company News

Novo enters RNAi via liver disease deal with Dicerna

...RNAi technology to its toolkit though a liver-focused deal with Dicerna. The partners will use Dicerna's...
...of 2.3 million shares at $21.93, a 14% premium to Dicerna's Friday close of $19.30. Dicerna...
...programs targeting cardiometabolic disorders; Dicerna can opt in to co-develop two programs during clinical development. Dicerna...
Items per page:
1 - 10 of 127
BioCentury | Apr 9, 2021
Deals

April 8 Quick Takes: Hologic buying Mobidiag for nearly $800M; plus Biogen-Bio-Thera, Dicerna royalty sale, a SPAC for LumiraDx, Cidara-Janssen and Chi-Med’s $100M

...This article has been updated to reflect that Dicerna is eligible for $60 million in milestones...
...in Phase III testing.Dicerna sells Oxlumo royalty rightsRoyalty Pharma plc (NASDAQ:RPRX) acquired the royalty interest of Dicerna Pharmaceuticals Inc....
...a 2020 non-exclusive IP deal between Dicerna and Alnylam related to the companies’ PH programs. Dicerna...
BioCentury | Oct 15, 2020
Product Development

Lingering questions as Vertex sheds $15B after Phase II setback

...AAT therapies, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and Dicerna Pharmaceuticals Inc....
...$300 million.That deal came six months after Dicerna...
BioCentury | Oct 9, 2020
Deals

Arrowhead gains Takeda firepower as it seeks edge over Dicerna in AAT-associated liver disease

...Takeda that could help it compete with Dicerna...
...exclusive rights. The deal comes six months after Dicerna Pharmaceuticals Inc....
...—its own DCR-A1AT, and Alnylam's ALN-AAT02. Dicerna...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

...manufacturing facility in Ireland, which it says will be operational in 2021. RNAi therapeutics company Dicerna Pharmaceuticals Inc....
...autoimmune diseases (see “Kira: Depleting Activated Dendritic Cells” ). Robin Sawka, BioCentury Staff Alexion Pharmaceuticals Inc. WuXi Biologics Inc. Dicerna Pharmaceuticals Inc. Valneva...
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...was director of the Center for Lymphoid Malignancies at Columbia University Medical Center. RNAi company Dicerna Pharmaceuticals Inc....
...of commercial development at Pfizer Inc. (NYSE:PFE) in 2009-12. Robin Sawka, BioCentury Staff TG Therapeutics Inc. FogPharma Gemini Therapeutics Inc. Dicerna Pharmaceuticals Inc. Lodo...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...and technical operations, effective May 4. Guyer was SVP of operations at BMS. RNAi company Dicerna Pharmaceuticals Inc....
...Nash will temporarily assume the role of executive chairman. Robin Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix...
BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

...in Europe” ). Alnylam, Dicerna developing RNAi liver disease therapies Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Dicerna Pharmaceuticals Inc....
...the pair also granted each other non-exclusive cross-licenses to their respective primary hyperoxaluria (PH) programs. Dicerna...
...opt in to ex-U.S. commercialization of the selected candidate. The cross-licenses for Alnylam's lumasiran and Dicerna's...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...those programs.” Nodelman’s RNA interests include Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Dicerna Pharmaceuticals Inc....
...by Novartis AG (NYSE:NVS) for $9.7 billion. An updated regulatory plan has not been disclosed. Dicerna...
BioCentury | Jan 11, 2020
Company News

Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV

...oligonucleotide stabilization technology in-licensed from Osaka University-spinout Luxna Biotech Co. Ltd. Several other companies, including Dicerna Pharmaceuticals Inc....
BioCentury | Nov 18, 2019
Company News

Novo enters RNAi via liver disease deal with Dicerna

...RNAi technology to its toolkit though a liver-focused deal with Dicerna. The partners will use Dicerna's...
...of 2.3 million shares at $21.93, a 14% premium to Dicerna's Friday close of $19.30. Dicerna...
...programs targeting cardiometabolic disorders; Dicerna can opt in to co-develop two programs during clinical development. Dicerna...
Items per page:
1 - 10 of 127